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F
or women with breast cancer requiring mastec-
tomy, breast reconstruction may improve body 
image and provide significant psychosocial 
benefits.1 Although autologous reconstruction tradi-
tionally has been associated with the highest patient 
satisfaction in terms of aesthetic outcomes,2–4 implant-
based reconstruction is by far the most common ap-
proach to postmastectomy breast reconstruction in 
the United States.5 Of approximately 92,000 breast 
reconstructions performed in 2012, slightly more 
than 72,000 were implant based, and of those, the 
vast majority (64,575) were 2-stage tissue expander/ 
implant reconstructions.5 Compared with autologous 
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Background: Tissue reinforcement with allogeneic or xenogeneic acellular 
dermal matrices (ADMs) is increasingly used in single-stage (direct-to-implant) 
and 2-stage implant-based breast reconstruction following mastectomy. ADMs 
allow surgeons to control implant position and obviate the need for submuscu-
lar implant placement. Here, we review the benefits and risks of using ADMs in 
implant-based breast reconstruction based on available data.
Methods: A comprehensive analysis of the literature with focus on recent 
publications was performed. Additional information regarding the proper 
use of ADMs was based on our institutional experience.
Results: ADM use may improve definition of the lateral confines of the breast 
and lower pole projection. It may facilitate direct-to-implant procedures and 
improve aesthetic outcomes. The effect of ADMs on complication rates re-
mains controversial. Known patient risk factors such as obesity, smoking, and 
radiotherapy should be considered during patient selection. For patients 
with healthy, well-vascularized skin envelopes, ADM-assisted direct-to-  implant 
reconstruction is a safe and cost-effective alternative to 2-stage implant 
  reconstruction, with low complication rates. ADMs may be used to treat 
  capsular contracture, and limited available data further suggest the   possibility 
that ADMs may reduce the risk of capsular contracture. Novel synthetic or bio-
synthetic tissue reinforcement devices with different physical and ease-of-use   
properties than ADMs are emerging options for reconstructive surgeons and   
patients who seek to avoid tissue products from human or mammalian  cadavers.
Conclusions: ADM-assisted implant-based breast reconstruction may improve 
aesthetic outcomes. However, appropriate patient selection, surgical tech-
nique, and postoperative management are critical for its success, including 
minimizing the risk of complications. (Plast Reconstr Surg Glob Open 2014;2:e192; 
doi: 10.1097/GOX.0000000000000140; Published online 4 August 2014.)
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reconstructions, implant-based reconstructions are 
simpler, take less time to perform, are less invasive, 
support faster patient recovery,2,6 and avoid the need 
for donor site surgery, which may cause significant 
postoperative deterioration of physical well-being.7 
In addition, they are believed to have more favorable 
third-party reimbursement limits.8
The increasing availability of acellular dermal ma-
trices (ADMs) prepared from human or animal cadav-
ers for tissue reinforcement provides plastic surgeons 
with a unique tool to improve aesthetic outcomes of 
implant-based reconstruction by expanding and re-
shaping the implant pocket, while further reducing 
the invasiveness of surgical intervention.9–15 The sub-
stantial pain caused by the serratus anterior elevation 
necessary for total or partial muscle coverage can be 
avoided, as lateral coverage is provided by the ADM. 
However, results of a prospective randomized study in 
70 patients who underwent immediate ADM-assisted 
or conventional submuscular tissue expander/im-
plant reconstruction after mastectomy revealed no 
significant differences between these patient groups 
in immediate postoperative pain or pain during the 
expansion phase.16 In addition to providing mechani-
cal stability, ADMs facilitate cellular and vascular infil-
tration during wound healing and tissue regeneration 
through incorporation of the matrix. Since the first 
publication of ADM-assisted primary breast recon-
struction in 2005,9 an increasing number of products 
have become available in the United States (Table 1). 
In Israel, AlloDerm (LifeCell Corp., Branchburg, 
N.J.), the prototypical ADM of human dermal origin, 
has been available since 2005 and SurgiMend (TEI 
Biosciences Inc., Boston, Mass.), a fenestrated ADM 
derived from fetal bovine dermis, has been available 
since 2008. Allogeneic ADMs are not extensively used 
in many European countries because of regulatory re-
strictions on human tissue products and cost consid-
erations favoring alternative products.18,19
In this review, we describe the benefits of tissue re-
inforcement in implant-based breast reconstruction, 
such as improved aesthetic outcomes, provide cost 
considerations, and discuss the risk of postoperative 
complications. Moreover, we provide recommenda-
tions based on our own experience for how the risk 
of complications can be minimized by appropriate 
patient selection, surgical technique, and postopera-
tive management.
IMMEDIATE IMPLANT-BASED 
RECONSTRUCTION WITH AND 
WITHOUT TISSUE REINFORCEMENT
Conventional Implant-based Reconstruction
Conventional implant-based reconstruction af-
ter mastectomy requires the creation of an implant 
pocket beneath the pectoralis major muscle for total 
or partial muscle implant coverage (Table 2). For to-
tal muscle coverage, elevation of the serratus anterior 
muscle is required for lateral coverage and support. 
Total muscle coverage limits the possible anterior 
and inferior projection and thus may lead to less 
than optimal aesthetic outcomes. Furthermore, be-
cause the size of the implant pocket that can initially 
be created with this approach is constrained by avail-
able skin and muscle tissue after the mastectomy, im-
mediate reconstruction generally requires a 2-stage 
procedure, in which a tissue expander is implanted 
first, then gradually expanded over several months, 
and eventually replaced by a permanent implant.21
Implant-based Reconstruction with ADMs
The use of ADMs enables the formation of larg-
er implant pockets and optimal implant position-
ing without the need for serratus anterior muscle 
elevation. Provided the skin is sufficiently healthy, 
ADM use in 2-stage reconstruction allows for more 
predictable tissue expander position, larger intra-
operative expander fill volumes, and fewer expansions 
compared with submuscular placement.13,22–25
An important aspect of ADM use is that it facili-
tates immediate direct-to-implant reconstruction 
Table 1.  Allogeneic and Xenogeneic Soft Tissue Reinforcement Devices Available in the United States17
Product
Year  
Introduced Manufacturer Material Origin Sterile
Hydration  
Time
AlloDerm 1994 LifeCell Corp. Human dermis No (aseptically processed) 10–40 min
AlloDerm Ready To Use 2012 LifeCell Corp. Human dermis Yes ≥2 min
DermaMatrix 2005 Synthes, Inc.  
(West Chester, Pa.)
Human dermis No (aseptically processed) 3 min
FlexHD 2007 Ethicon, Inc. Human dermis No (aseptically processed) None
AlloMax ≥2009 Davol Inc. (Warwick, R.I.) Human dermis Yes “Rapidly”
Repriza 2010 Specialty Surgical Products, 
Inc. (Victor, Mont.)
Human dermis Yes None
Strattice 2008 LifeCell Corp. Porcine dermis Yes ≥2 min
Veritas Collagen Matrix 2001 Synovis (St Paul, Minn.) Bovine pericardium Yes None
SurgiMend 2006 TEI Biosciences Inc. Fetal bovine dermis Yes 60 s  Scheflan and Colwell • Tissue Reinforcement for Breast Implants
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(Table 2, Fig. 1) in appropriately selected patients 
by allowing precise positioning of a full-sized per-
manent implant, with favorable aesthetic outcomes 
and minimal risk of implant displacement, visibil-
ity, rippling, or extrusion.10–12,20,26–28 Moreover, ADM 
materials that are not completely resorbed help 
prevent pectoralis muscle retraction and offer addi-
tional soft tissue coverage in the lower pole of the 
breast.   Experience from 331   consecutive immediate 
direct-to-implant reconstructions performed with 
AlloDerm at the Massachusetts General Hospital 
suggests that this approach is associated with favor-
able aesthetic outcomes and low complication rates 
in patients with thick, well-vascularized skin flaps 
after skin-sparing or nipple-sparing mastectomy.20 
Similarly, the use of a SurgiMend in 341 consecutive 
Table 2.  Surgical Techniques of Total and Partial Muscle Coverage and of ADM-assisted Direct-to-implant 
Reconstruction
Total muscle 
 coverage
The pectoralis major muscle is elevated lateral to medial by electrocautery after the lateral edge has 
been identified. The inferior and medial origins are maintained. The serratus anterior muscle is 
elevated over the fourth, fifth, and sixth ribs by electrocautery. The superior portion of the rectus 
abdominis fascia or muscle may be included in the dissection of the muscular pocket to facilitate 
positioning of the tissue expander and help prevent superior malposition. One or 2 closed-suction 
drains are placed to facilitate drainage and help prevent seroma.
Partial muscle 
 coverage
The pectoralis muscle is elevated and partially released inferiorly to allow greater lower pole expan-
sion. The medial most sternal origin should be released inferiorly to allow the implant to fit medially 
and obtain cleavage. This typically corresponds to the 4 and 8 o’clock positions on the chest wall but 
may be advanced to the 3 or 9 o’clock positions if necessary. Sutures are typically used to prevent 
retraction of the pectoralis muscle, and the serratus muscle is often elevated to help cover the 
expander laterally and prevent lateral malposition
ADM-assisted 
direct-to-implant 
reconstruction
In one technique, the pectoralis major muscle is elevated from the chest wall inferiorly up to the 3 or 
9 o’clock position medially, and a tailored ADM is placed in the pocket and sewn to the   pectoralis 
muscle. In another technique, the pectoralis major muscle is elevated up to the 4 or 8 o’clock 
position medially, and a rectangular ADM is sewn to the inframammary fold, if present and well 
preserved, or to the thoracic fascia to create a new fold. After placement of the implant into the 
subpectoralis/sub-ADM pocket, a drain each is placed into the pocket along the inframammary fold 
and into the lateral pocket margin.10,20
Fig. 1. Use of aDM in implant-based breast reconstruction. Shown are the techniques prac-
ticed at the assuta Medical center (aMc), Tel aviv (a)17 and the Massachusetts General Hospital 
(MGH), Boston (B).10,20 The inferior origin of the pectoralis major is released on the aponeurosis 
of the external oblique and on the inferior sternum, with pectoralis elevation up to the 3 and 
9 o’clock position (aMc) or the 4 and 8 o’clock position (MGH). a tailored fenestrated semioval 
(aMc) or a standard rectangular (MGH) aDM sheet is sewn inferiorly to the thoracic fascia or 
inframammary fold (if intact) and laterally to the thoracic fascia to form the implant pocket. in 
the aMc technique, the semioval aDM is split, and the medial and lateral tails are sutured to 
the pectoralis major with deep overlap of the tails underneath the muscle (a). in the MGH tech-
nique, the rectangular aDM is sewn edge to edge to the pectoralis major without overlap (B).PRS GO • 2014
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immediate implant-based reconstructions after total 
skin-sparing mastectomy, including 270 direct-to-
implant reconstructions, performed between 2001 
and 2011 at the Assuta Medical Center in Tel Aviv, 
Israel, provided superior aesthetic results and simi-
lar rates of complications compared with traditional 
procedures.17
In the past, patient satisfaction tended to be lower 
with implant-based rather than autologous recon-
struction,3 which may be due in part to the limitations 
in shaping the implant pocket during conventional 
implant-based procedures. In our experience, the ad-
vent of ADM and nipple-sparing procedures, includ-
ing ADM-assisted direct-to-implant reconstruction, 
has allowed for significant improvements in overall 
aesthetic results of implant-based reconstruction, with 
the potential to increase patient satisfaction scores in 
the future. Furthermore, evaluation of aesthetic out-
comes of 183 tissue expander–based reconstructions 
performed at a single institution showed that ADM 
use (58 reconstructions) was associated with signifi-
cantly higher aesthetic scores compared with total 
submuscular reconstruction (125 reconstructions).29
PATIENT RISK FACTORS 
FOR COMPLICATIONS AND 
RECONSTRUCTIVE FAILURE
A number of database analyses consistently identi-
fied high body mass index and smoking as indepen-
dent risk factors for complications and/or implant 
loss.30–32 For 1170 two-stage breast reconstructions 
performed over a 2-year period, smoking, obesity, and 
hyper tension each increased the odds of reconstructive 
failure by factors of 5, 7, and 4, respectively.30 For more 
than 14,000 reconstructions with or without ADM cap-
tured in the Tracking Outcomes and Operations in 
Plastic Surgery (TOPS) database between 2008 and 
2011, high body mass index, smoking, and diabetes 
were independent risk factors for expander/implant 
loss.31 ADM use seems to have no substantial influence 
on patient-related risk factors.31,33 A recent analysis of 
data from the American College of Surgeons National 
Surgical Quality Improvement Program, which identi-
fied smoking and body mass index as independent risk 
factors for short-term complications, found no statisti-
cally significant risk differences between immediate 
ADM-assisted (n = 1717) and submuscular (n = 7442) 
tissue expander reconstruction.32
ADM USE AND POSTOPERATIVE 
COMPLICATIONS
A persistent concern among plastic surgeons is 
whether ADMs increase the risk of short-term com-
plications, given the conflicting findings from retro-
spective studies,13,16,20,24,25,33–43 systematic reviews,23,44 
and meta-analyses.22,45,46 However, although meta-
analyses (level III evidence) found increased risks 
of infection, seroma, and/or implant loss associated 
with ADM use,22,45,46 some recent large studies (level II 
or III evidence) not included in these analyses found 
similar or lower complication rates for ADM-assisted   
versus traditional 2-stage reconstruction.20,25,35,37 For   
example, a comparative study of 479 implant-based 
reconstructions found no difference in total com-
plication rates or rates of infection and seroma 
between ADM-assisted direct-to-implant reconstruc-
tion compared with 2-stage tissue expander/implant 
reconstruction without ADM (Table 3).20 Similarly, 
in a recent prospective cohort study, ADM use was 
associated with significant reductions in expander/
implant loss (Table 2) and unexpected returns to 
the operation room.35 These findings suggest that 
ADM use itself is not an independent risk factor for 
complications and that the large discrepancies in 
findings among different institutions may be attrib-
utable to other factors. This view is supported by the 
results of recent, large-scale National Surgical Qual-
ity Improvement Program and TOPS analyses.31,47 
Although the TOPS analysis showed that ADM use 
(versus no ADM use) was associated with a statisti-
cally significant increase in the risk of expander/ 
implant loss (odds ratio, 1.42; 95% confidence inter-
val, 1.04–1.94; P = 0.026), the absolute risk increase 
was only 0.7%.31
In our experience, the vast majority of complica-
tions attributed to ADM-assisted reconstruction are 
avoidable by appropriate patient selection and sur-
gical technique. An emerging consensus on the im-
portance of these factors is reflected in the recently 
published joint guidelines from the Association of 
Breast Surgery and the British Association of Plastic, 
Reconstructive and Aesthetic Surgeons48 and recom-
mendations by other experts in the field.49,50 Effec-
tive coordination of mastectomy and reconstructive 
surgery to ensure optimal viability of the skin en-
velope may further improve outcomes. Familiarity 
of the reconstructive surgeon with optimal device-
specific techniques also is crucial for avoiding com-
plications. In 331 consecutive ADM-assisted 1-stage 
implantations conducted between 2006 and 2009 at 
the Massachusetts General Hospital, increasing ex-
perience of the surgeons and better communication 
with the breast surgeon substantially reduced the 
incidence of skin necrosis, resulting in a significant 
2-fold reduction in total complication rates from 
the surgeons’ first to subsequent years of perform-
ing the procedure (21.4%–10.9%; P < 0.02).20 How-
ever, if skin viability is questionable at the time of 
the mastectomy, total muscle coverage (rather than   Scheflan and Colwell • Tissue Reinforcement for Breast Implants
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partial muscle release with or without ADM) should 
be considered even if this may negatively affect the 
final aesthetic outcome (Fig. 2).
THE RISK OF CAPSULAR 
CONTRACTURE
Capsular contracture is a common risk of im-
plant-based reconstruction, particularly in the set-
ting of radiotherapy.51–54 A variety of factors may 
contribute to development of capsular contracture, 
including but not limited to insufficient sterility 
during surgery, hematoma, mechanical strain on 
the inferior skin envelope, type and surface proper-
ties of the implant, and radiation therapy.55,56 It has 
been suggested that the use of ADMs may minimize 
capsular contracture by reducing pressure on the 
inferior breast skin envelope,20 which in turn may 
reduce fibroblast stimulation and inflammation.57,58 
In a retrospective comparison of 2-stage reconstruc-
tion with and without ADM use during expander 
implantation in 203 patients, the capsular contrac-
ture rate was significantly lower for ADM-assisted 
reconstructions (3.8% versus 19.4%; P < 0.001) 
at a mean follow-up after implant exchange of 29 
months.37 Moreover, a remarkably low capsular 
contracture rate of only 0.4% was observed in an 
8-year study of 466 ADM-assisted direct-to-implant 
breast reconstructions with a mean follow-up of 
29 months,27 and ADM use, including complete 
implant coverage, has been used successfully in 
the treatment of capsular contracture.55,59 How-
ever, given that the risk of implant-related capsular 
contracture increases over time,60 it remains to be 
demonstrated whether ADMs reduce the long-term 
risk of capsular contracture. Furthermore, it is pres-
ently unclear whether non–ADM-based tissue rein-
forcements can influence the incidence of capsular 
contracture.
EFFECT OF RADIOTHERAPY
A major concern with implant-based breast recon-
struction is the effect of radiation therapy on compli-
cation rates.61 Radiation therapy given before or after 
mastectomy has been associated with significantly 
increased rates of major complications,62 including 
implant removal or replacement25,63 and capsular 
contracture.51,53,54 However, a recent systematic review 
found that ADM did not increase the complication 
rate in the setting of radiotherapy.64 Similarly, an-
other recent literature review concluded that ADM 
use essentially had a neutral effect on postoperative 
complications among patients who received adjuvant 
radiation therapy after implant-based reconstruc-
tion,65 and results of a recent retrospective study even 
suggested that ADM use may significantly reduce the 
odds of complications (including explantation) in the 
setting of postmastectomy radiation therapy.25
Among patients who received a total of 479 ADM-
assisted direct-to-implant or conventional 2-stage re-
constructions at the Massachusetts General Hospital, 
radiotherapy was associated with an increased rate 
of early complications. Among patients who received 
radiation, the highest complication rate was seen in 
the setting of preoperative irradiation and conven-
tional 2-stage reconstruction (41.1%), whereas the 
lowest rate was seen in direct-to-implant reconstruc-
tions with postoperative radiation (16.7%).20 The im-
portance of timing of postmastectomy radiotherapy 
was also demonstrated in a prospective, controlled 
study of 257 patients undergoing subpectoral 2-stage 
breast reconstruction.66 Patients who received radio-
therapy on the tissue expander had a significantly 
higher failure rate (40%) than those who received 
radiotherapy on the permanent implant (6.4%) or 
received no radiotherapy (2.3%; P < 0.0001).66
Radiation therapy also seems to affect capsular 
contracture rates after ADM-assisted implant-based 
Fig. 2. algorithm for implant-based reconstruction.20 Reprinted with permission from col-
well aS, Damjanovic B, Zahedi B, et al. Retrospective review of 331 consecutive immediate 
single-stage implant reconstructions with acellular dermal matrix: indications, complica-
tions, trends, and cost. Plast Reconstr Surg. 2011;128:1170–1178.  Scheflan and Colwell • Tissue Reinforcement for Breast Implants
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breast reconstruction. The overall rate of clinically 
significant capsular contracture (grade III/IV) 
among 341 reconstructions at the Assuta Medical 
Center was only 2.0%. Remarkably, capsular contrac-
ture occurred exclusively in patients who previously 
received preoperative or postoperative radiation 
therapy at a rate of 12.3%.17 In a study of ADM-assisted  
2-stage reconstruction in 289 women, radiation 
therapy before mastectomy and at expander stage 
resulted in dramatically increased rates of infection 
(53% and 73%, respectively, versus 1.4% without 
radiation) and grade III/IV capsular contractures 
(41% and 61%, respectively, versus 1.4% without ra-
diation), although eventual explantation was avoid-
ed in most cases.54 Thus, although the use of ADM in 
implant-based reconstruction may reduce the risk of 
capsular contracture, it remains to be demonstrated 
whether this benefit extends to patients who receive 
pre- or postoperative radiation therapy.
COST CONSIDERATIONS
Recent cost analyses including the costs of prob-
able complications in addition to physician and hos-
pital fees estimate that ADM-assisted direct-to-implant 
reconstruction may result in moderate to substantial 
cost savings compared with traditional 2-stage implant 
reconstruction.67,68 At the Massachusetts General Hos-
pital, overall hospital charges of the 2 procedures did 
not differ significantly (P = 0.8) because the substan-
tially lower professional fees charged by anesthesiolo-
gists and surgeons for ADM-assisted direct-to-implant 
reconstruction were largely offset by higher hospital 
charges.20 An important cost factor when using tissue 
reinforcement can be the costs of the tissue support 
itself, particularly if AlloDerm is used. However, these 
costs may decrease with the increasing availability of 
lower cost xenogeneic ADMs18 and alternative tissue 
reinforcement devices.19,69 Furthermore, overall cost 
savings may potentially be larger than currently esti-
mated if future research demonstrated that the use of 
ADM-assisted procedures substantially reduces the in-
cidence of implant loss, capsular contracture, time off 
from work, and corrective surgery. The usage of ADM 
in 2-stage reconstruction increases the material costs 
for the procedure. For cost savings to be realized in 
this setting, a decreased need for revisions, shorter op-
erative time, and/or lower complication rates would 
need to be demonstrated in a cost–benefit analysis.
NON-ADM OPTIONS FOR SOFT TISSUE 
REINFORCEMENT
ADMs may vary in their chemical composition 
and physical properties, with the potential to affect 
the quality and timing of tissue regeneration,70–72 
and the risk of complications.18,73–80 Differences in 
material-associated risk of inflammation, thickness, 
requirements for hydration, and sterility may affect 
the handling facility of ADMs and their ability to si-
multaneously provide adequate structural support 
and sufficient pliability.81 Patients who do not accept 
cadaver material being part of their reconstructed 
breasts would benefit from alternative products with 
appropriate physical and ease-of-use properties that 
are either synthetic or made from biomaterials other 
than ADMs.
TiLOOP Bra (pfm medical titanium, Nuremberg, 
Germany), a nonabsorbable titanium-coated pro-
pylene mesh approved for breast reconstruction in 
Europe, was retrospectively evaluated in 231 breast 
reconstructions. Explantation (7.8%) was the most 
common major complication, with skin necrosis 
and capsule fibrosis identified as significant risk fac-
tors in multivariate analysis.19 TIGR Matrix (Novus 
Scientific, Uppsala, Sweden), a synthetic, long-term 
resorbable surgical mesh,82 may be beneficial as tem-
porary tissue reinforcement, but clinical experience 
to date is very limited.83 A retrospective review of 76 
direct-to-implant reconstructions with Vicryl mesh 
(Ethicon, Inc., Somerville, N.J.) in 50 consecutive pa-
tients was associated with complications in 5 breasts 
(6.6%) including 1 implant loss (1.3%) consequent 
to infection.69 Long-term capsular contracture rates 
were not reported.69
SERI (Allergan, Inc., Irvine, Calif.), a long-term 
bioresorbable, silk-derived surgical scaffold,84–86 re-
ceived 510(k) clearance from the US Food and Drug 
Administration for use as soft tissue reinforcement 
in plastic and reconstructive surgery. In a single-arm 
prospective multicenter study of 2-stage implant-
based breast reconstruction with SERI in the United 
States (NCT01256502), complications at 1-year fol-
low-up (n = 105) included necrosis (6.7%), hema-
toma (4.8%), seroma (5.7%), implant loss (3.8%), 
cellulitis [minor breast infection requiring antibiotic 
treatment (2.9%)], breast infection [major, requir-
ing surgical intervention (1.0%)], and capsular con-
tracture (1.9%), but were considered unrelated to 
the use of SERI by the investigators.87
CONCLUSIONS
Tissue reinforcement in implant-based breast 
  reconstruction may reduce the invasiveness of im-
plant-based procedures and improve aesthetic out-
comes.  Appropriate patient selection, proper surgical 
technique, and adjusted postoperative management 
are critical for the success of ADM-assisted reconstruc-
tion, including minimizing the risk of complications. 
For qualifying patients with healthy, well-vascularized   
skin envelopes, ADM-assisted direct-to-implant   PRS GO • 2014
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reconstruction is a safe and cost-effective alternative 
to 2-stage implant reconstruction that can provide 
excellent aesthetic results. Known patient risk factors 
for implant-based reconstruction, such as obesity and 
smoking, also apply to ADM-assisted reconstruction 
and should be considered during patient selection.
The availability of novel synthetic or biosynthet-
ic tissue reinforcement devices that have different 
physical and ease-of-use properties than ADMs may 
enhance the ability to refine surgical techniques to 
further optimize aesthetic outcomes and minimize 
complications. 
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